Johnson & Johnson (JNJ)vsLexicon Pharmaceuticals Inc (LXRX)
JNJ
Johnson & Johnson
$232.77
-2.08%
HEALTHCARE · Cap: $536.54B
LXRX
Lexicon Pharmaceuticals Inc
$1.85
-2.12%
HEALTHCARE · Cap: $835.09M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 138266% more annual revenue ($96.36B vs $69.64M). JNJ leads profitability with a 21.8% profit margin vs -37.5%. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
LXRX
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-71.4%
Fair Value
$135.80
Current Price
$232.77
$96.97 premium
Intrinsic value data unavailable for LXRX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Revenue surging 1572.0% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Smaller company, higher risk/reward
ROE of -12.9% — below average capital efficiency
Earnings declined 63.4%
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : LXRX
The strongest argument for LXRX centers on Revenue Growth, Debt/Equity. Revenue growth of 1572.0% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : LXRX
The primary concerns for LXRX are Market Cap, Return on Equity, EPS Growth.
Key Dynamics to Monitor
JNJ profiles as a mature stock while LXRX is a hypergrowth play — different risk/reward profiles.
LXRX carries more volatility with a beta of 1.07 — expect wider price swings.
LXRX is growing revenue faster at 1572.0% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 29/100), backed by strong 21.8% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Lexicon Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development and commercialization of pharmaceutical products. The company is headquartered in The Woodlands, Texas.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?